-- Creative Bioarray, one of the leading providers of biotechnology products and services, which aims to accelerate the research in biology and pharmaceutical fields, recently announced the release of its flagship Patient-Derived Organoid Drug Screening Services.
At the forefront of this innovation are Patient-Derived Organoids (PDOs)—three-dimensional (3D) cell culture models meticulously derived from patient samples, including tumor tissues. Recent findings suggest that these PDOs exhibit response characteristics to targeted therapies and chemotherapy that closely align with those of the patients from whom they originate. These similarities highlight their potential to accurately predict drug efficacy, making them key tools in the fields of new drug discovery and personalized medicine.
Baed on its specialized platforms and dedicated research staff, Creative Bioarray offers cutting-edge PDO-based drug screening services designed to empower researchers and pharmaceutical companies. These services help researchers identify promising drug candidates from extensive or customized compound libraries, streamlining the research process while enabling a comprehensive assessment of drug efficacy prior to costly clinical trials.
“Our advanced PDO-based workflows are engineered to deliver precise and dependable results,” remarked Hannah Cole, the marketing director of Creative Bioarray. “By harnessing the power of patient-specific models, we are advancing the drug development process and fostering a more personalized approach to treatment.”
The use of PDOs marks a transformative shift in personalized medicine, enabling researchers to more effectively tailor treatments to individual patients. This approach, combining cutting-edge science with the urgent need for more personalized treatment strategies, has significant implications for improving patient outcomes.
Creative Bioarray has developed an advanced, automated high-throughput screening system that is small-scale, rapid, sensitive, and accurate, capable of simultaneously screening thousands of compounds. This high-throughput approach significantly accelerates drug development and reduces costs. Organoid assays suitable for high-throughput screening (HTS) require high sensitivity and robustness. Creative Bioarray uses a 3D cell viability assay to assess organoid cell viability. This assay quantifies the number of viable cells in PDO cultures by quantifying ATP levels in metabolically active cells.
About Creative Bioarray
Creative Bioarray is a leading biotechnology company focused on providing advanced solutions for drug discovery and development. Our mission is to accelerate drug discovery and advance personalized medicine through precise screening and analysis tailored to the unique characteristics of individual patients. Additionally, Creative Bioarray provides a variety of cell-related products and services dedicated to advancing the life sciences industry.
Contact Info:
Name: Hannah Cole
Email: Send Email
Organization: Creative Bioarray
Address: Shirley, NY 11967, USA
Phone: 16313868241
Website: https://www.creative-bioarray.com/
Release ID: 89166136
Google
RSS